JW Holdings Corp is a Korea-based company principally engaged in the production and sale of pharmaceuticals. The Company is principally engaged in the production and sale of pharmaceuticals such as antibiotics, antifungal agents, blood and body fluids substitutes, hyperlipidemia drugs, electrolyte additives, angina pills and digestive medicines. The Company is also engaged in the manufacture and sale of diagnostic equipment for hematology, immunology and others. In addition, the Company is engaged in the holding businesses.

Employees

127

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	₩3,860.00	+0.92%	60,345
26-07-23	₩3,825.00	+0.66%	24,590
26-07-22	₩3,800.00	-0.39%	51,326
26-07-21	₩3,815.00	+1.60%	80,118
26-07-20	₩3,755.00	-3.84%	56,274

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-07-24			5-day change	1st Jan Change
3,860.00 ^KRW	+0.92%		-1.15%	+7.52%

05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	267B 183M 161M 149M 137M 258M 17.61B 262M 1.77B 693M 8.66B 687M 672M 29.94B	P/E 2024	3.45x	P/E 2025	4.27x
Enterprise Value	537B 368M 323M 300M 276M 518M 35.42B 526M 3.57B 1.39B 17.42B 1.38B 1.35B 60.21B	EV / Sales 2024	0.65x	EV / Sales 2025	0.53x
Free-Float	41.26%	Yield 2024	5.13%	Yield 2025	-

05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-04	JW Holdings Corporation announces Annual dividend, payable on April 24, 2026	CI
11-14	JW Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Jw Holdings Q3 operating profit 5 billion won, up 38.4% from year earlier	RE
25-08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-31	Jw Holdings Q2 operating profit 3.4 billion won, down 82% from year earlier	RE
25-07-03	Sound Smithy Co Ltd announced that it has received KRW 200 million in funding from JW Holdings Corporation	CI
25-06-25	Sound Smithy Co Ltd announced that it expects to receive KRW 200 million in funding from JW Holdings Corporation	CI
25-06-25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
25-06-25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
25-06-23	JW Holdings Corporation's Equity Buyback announced on March 24, 2025 has expired with 714,439 shares, representing 1.02% for KRW 2,500 million.	CI
25-05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

23-10-04	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mercredi 4 octobre 2023
23-10-04	Kering : Seán McGirr nommé Directeur de la Création d'Alexander McQueen
23-10-03	Kering : nouveau directeur création chez Alexander McQueen
23-10-03	Kering nomme Seán McGirr directeur de la création chez Alexander McQueen
23-08-18	El Kospi de Corea cae un 0,6%, su mayor racha de pérdidas desde junio de 2022 -- Market Talk

JW Holdings Corporation Stock

Stocks

A096760

KR7096760004

Pharmaceuticals

Valuation: JW Holdings Corporation

Chart: JW Holdings Corporation

Latest news : JW Holdings Corporation

News in other languages: JW Holdings Corporation

Quotes and Performance

Course Extremes

Managers and Directors: JW Holdings Corporation

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.92%
1 week	-1.15%
Current month	+5.03%
1 month	+4.32%
3 months	-10.96%
6 months	+4.18%
Current year	+7.52%

1 week	3,700	3,935
1 month	3,585	3,985
Current year	3,300	4,495
1 year	3,145	4,495
3 years	2,650	4,495
5 years	2,536.65	4,495
10 years	2,536.65	16,326.2

Manager	Title	Age	Since
Seong-Nam Cha CEO	Chief Executive Officer	69	2024-03-26
Kyung-Ha Lee CEO	Chief Executive Officer	62	-
Ji-Woo Choi DFI	Director of Finance/CFO	60	2020-03-26

Director	Title	Age	Since
Kyung-Ha Lee CHM	Chairman	62	-
Chan-Yeop Yeom BRD	Director/Board Member	64	2020-03-26
Ji-Woo Choi BRD	Director/Board Member	60	2020-03-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/7/24	Kyung-Ha Lee	Free	Chief Executive Officer	412,069	0.5574%
2/7/24	Sung-Kweon Han	Free	Chief Executive Officer	215	0.0003%
2/7/24	Jun-gu Lee	Free		30	0.0000%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JW HOLDINGS CORPORATION	+0.92%	-1.15%	+4.18%	+4.99%	183M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.66%	+0.44%	+14.25%	+77.26%	48.36B
OTSUKA HOLDINGS CO., LTD.	+2.20%	+1.41%	+57.98%	+112.68%	35.8B
CIPLA LIMITED	+1.26%	-0.57%	-7.95%	+33.74%	11.83B
ZYDUS LIFESCIENCES LIMITED	-0.46%	-3.06%	+13.55%	+78.32%	11.48B
KRKA, D. D.	-0.37%	-0.37%	+37.53%	+140.99%	9.01B
ONO PHARMACEUTICAL CO., LTD.	+1.52%	+0.39%	+49.34%	-7.78%	6.99B
GEDEON RICHTER	-0.17%	-2.92%	+11.72%	+32.23%	6.7B
GLENMARK PHARMACEUTICALS LIMITED	-0.59%	-1.95%	+2.18%	+179.57%	6.42B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-7.92%	-13.61%	-33.87%	-3.07%	5.3B
Average	-0.43%	-1.62%	+14.89%	+64.89%	14.21B
Weighted average by Cap.	+0.12%	-0.44%	+24.09%	+81.92%

	2024	2025
Net sales	888B 608M 534M 497M 456M 856M 58.54B 869M 5.9B 2.3B 28.78B 2.28B 2.23B 99.51B	970B 664M 583M 542M 498M 935M 63.94B 949M 6.44B 2.52B 31.43B 2.49B 2.44B 109B
Net income	62.62B 42.88M 37.66M 35.02M 32.14M 60.39M 4.13B 61.32M 416M 162M 2.03B 161M 157M 7.02B	58.5B 40.06M 35.19M 32.72M 30.03M 56.42M 3.86B 57.29M 389M 152M 1.9B 150M 147M 6.56B
Net Debt	362B 248M 218M 202M 186M 349M 23.85B 354M 2.4B 939M 11.73B 930M 910M 40.54B	270B 185M 162M 151M 139M 260M 17.81B 264M 1.79B 701M 8.76B 694M 679M 30.28B